Merck & Co., Inc. (MRK)
| Market Cap | 287.52B +12.9% |
| Revenue (ttm) | 65.01B +1.3% |
| Net Income | 18.25B +6.6% |
| EPS | 7.28 +8.0% |
| Shares Out | 2.48B |
| PE Ratio | 15.91 |
| Forward PE | 22.45 |
| Dividend | $3.40 (2.94%) |
| Ex-Dividend Date | Mar 16, 2026 |
| Volume | 25,793,360 |
| Open | 111.67 |
| Previous Close | 113.37 |
| Day's Range | 111.44 - 118.46 |
| 52-Week Range | 73.31 - 118.46 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 115.21 (-0.54%) |
| Earnings Date | Feb 3, 2026 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $115.21, which is a decrease of -0.54% from the latest price.
News
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways
Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.
Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow
Merck & Co., Inc. (NYSE: MRK) on Tuesday reported its fourth-quarter adjusted earnings per share of $2.04, surpassing consensus estimates of $2.01, a jump from $1.72 a year ago.
Merck tops Q4 earnings expectations but issues weaker 2026 outlook
Merck closed the fourth quarter with earnings and revenue ahead of Wall Street estimates, supported by strong demand for its blockbuster cancer drug Keytruda and accelerating sales from newer medicine...
Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year
Merck's stock falls as the full-year revenue and profit outlooks were below expectations.
Merck Earnings Top Estimates. Why the Stock Is Falling.
Merck says 2026 earnings will take a hit due to its pending takeover of Cidara Therapeutics.
Merck Expects Slower Earnings Growth As It Spends on Acquisitions
Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions.
Merck forecasts 2026 sales below estimates on patent losses
Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates as the loss of patent exclusivity on diabetes drug Januvia and other medicines will hit harder than analysts are proje...
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But Merck posted a modest 2026 outlook that fe...
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results.
5 Stocks That Could Outperform Even in a Pullback
Kenny Polcari, Senior Market Strategist of Slatestone Wealth shares his top 5 stock picks for 2026 that could hold up even if the market gets choppy.
What's Fueling The Rally In Merck Stock?
Merck (MRK)'s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a significant profit jump and heightened investor confidence.
Merck Announces Second-Quarter 2026 Dividend
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Second-Quarter 2026 Dividend.
Overlooked Stock: RVMD Sells After MRK Turns Away
Revolution Medicines (RVMD) reversed a lot of its recent rally on Monday after the Wall Street Journal reported that Merck (MRK) is no longer looking to buy the biotech firm. However, as George Tsilis...
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse
Merck & Co., Inc. (NYSE: MRK) has reportedly ended discussions to acquire cancer drug developer Revolution Medicines, Inc. (NASDAQ: RVMD) after the two sides disagreed on valuation.
Merck no longer in talks to buy Revolution Medicines, WSJ reports
Merck is no longer in discussions to buy cancer drug developer Revolution Medicines , the Wall Street Journal reported on Sunday.
Merck No Longer in Talks to Buy Revolution Medicines
The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at around $30 billion.
Top 10 Dividend Stocks For Uncertain Times
Stocks entered 2026 on a positive note before a global sell-off wiped out gains, driven by tariff tensions, a Greenland tug-of-war, and Japan's bond crisis. In this uncertain environment, dividends ca...
Merck partners with global health coalition to develop affordable Ebola vaccine
Merck and the Coalition for Epidemic Preparedness Innovations said on Wednesday they have partnered on a $30 million program to develop an updated version of the drugmaker's Ebola vaccine aimed at imp...
Moderna, Merck Report Positive Results From Cancer-Vaccine Study
Moderna and Merck's cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.
Moderna, Merck's skin cancer vaccine shows sustained benefit after five years
Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in combination with Keytruda, reduced the risk of recurrence or death by 49% in a mid-stage trial.
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510;...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Is Merck Stock A Trap At $110?
Merck stock surged more than 10% in a month after management delivered a confidence shock on January 12th. They're now projecting that their next-generation drugs—treatments for cardiometabolic, respi...